{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Polyneuropathies",
    "query": {
      "condition": "Polyneuropathies"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 311,
    "total_pages": 32,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Polyneuropathies&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T08:09:23.950Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04980872",
      "title": "A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)"
      ],
      "interventions": [
        {
          "name": "Miransertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "2 Years to 120 Years"
      },
      "enrollment_count": 60,
      "start_date": "2021-11-02",
      "completion_date": "2030-02-07",
      "has_results": false,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-05-22T08:09:23.950Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04980872"
    },
    {
      "nct_id": "NCT02465359",
      "title": "Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Subcutaneous (Human)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 15,
      "start_date": "2014-09",
      "completion_date": "2021-05",
      "has_results": true,
      "last_update_posted_date": "2024-10-08",
      "last_synced_at": "2026-05-22T08:09:23.950Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02465359"
    },
    {
      "nct_id": "NCT03050827",
      "title": "Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic; Neuropathic, Polyneuropathy (Manifestation)"
      ],
      "interventions": [
        {
          "name": "3% oxybutynin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eastern Virginia Medical School",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 51,
      "start_date": "2014-05-01",
      "completion_date": "2017-12-31",
      "has_results": false,
      "last_update_posted_date": "2019-02-22",
      "last_synced_at": "2026-05-22T08:09:23.950Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03050827"
    },
    {
      "nct_id": "NCT06452914",
      "title": "Clinical Outcomes Related to Treatment of Distal Symmetric Polyneuropathy Using Semiconductor Embedded Therapeutic Socks",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetic Neuropathy"
      ],
      "interventions": [
        {
          "name": "Semiconductor Embedded Therapeutic Socks",
          "type": "DEVICE"
        },
        {
          "name": "Placebo Socks",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Endocrine Research Solutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 80,
      "start_date": "2024-06-11",
      "completion_date": "2025-06",
      "has_results": false,
      "last_update_posted_date": "2025-02-25",
      "last_synced_at": "2026-05-22T08:09:23.950Z",
      "location_count": 1,
      "location_summary": "Roswell, Georgia",
      "locations": [
        {
          "city": "Roswell",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06452914"
    },
    {
      "nct_id": "NCT00784693",
      "title": "A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "Tanezumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 48,
      "start_date": "2008-12-18",
      "completion_date": "2010-04-05",
      "has_results": true,
      "last_update_posted_date": "2021-04-30",
      "last_synced_at": "2026-05-22T08:09:23.950Z",
      "location_count": 30,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • San Diego, California + 20 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00784693"
    },
    {
      "nct_id": "NCT03013777",
      "title": "A Trial of Cognitive Behavioral Therapy in Familial Dysautonomia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dysthymia",
        "Anxiety Disorders",
        "Familial Dysautonomia",
        "Paroxysmal Hypertension",
        "Autosomal Recessive Disease"
      ],
      "interventions": [
        {
          "name": "8-week CBT Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2016-12-06",
      "completion_date": "2018-07-20",
      "has_results": false,
      "last_update_posted_date": "2019-01-29",
      "last_synced_at": "2026-05-22T08:09:23.950Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03013777"
    },
    {
      "nct_id": "NCT01449370",
      "title": "Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "TAK-117",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2011-10",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2017-03-09",
      "last_synced_at": "2026-05-22T08:09:23.950Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Detroit, Michigan • Dallas, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01449370"
    },
    {
      "nct_id": "NCT05095844",
      "title": "National Vaccine Adverse Event Reporting Survey and Etiology",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19",
        "Vaccine Adverse Reaction",
        "Vaccine Reaction",
        "Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use",
        "Corona Virus Infection",
        "Blood Clot",
        "Thrombocytopenia",
        "Neuritis",
        "Vasculitis",
        "Influenza",
        "Guillain-Barré",
        "GWAS",
        "Genetic Sequencing"
      ],
      "interventions": [
        {
          "name": "vaccinated",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Neuroganics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "5 Years to 99 Years"
      },
      "enrollment_count": 100000,
      "start_date": "2022-03-15",
      "completion_date": "2024-04-01",
      "has_results": false,
      "last_update_posted_date": "2022-03-18",
      "last_synced_at": "2026-05-22T08:09:23.950Z",
      "location_count": 1,
      "location_summary": "Northglenn, Colorado",
      "locations": [
        {
          "city": "Northglenn",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05095844"
    },
    {
      "nct_id": "NCT02108769",
      "title": "Yogic Breathing Changes Salivary Components",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Neurodegenerative Diseases",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Yogic Breathing",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Attention Control",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2013-10",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2014-04-09",
      "last_synced_at": "2026-05-22T08:09:23.950Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02108769"
    },
    {
      "nct_id": "NCT00733902",
      "title": "Tanezumab in Osteoarthritis of the Knee",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis",
        "Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "tanezumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 697,
      "start_date": "2008-09-15",
      "completion_date": "2010-01-14",
      "has_results": true,
      "last_update_posted_date": "2021-03-22",
      "last_synced_at": "2026-05-22T08:09:23.950Z",
      "location_count": 82,
      "location_summary": "Phoenix, Arizona • Danbury, Connecticut • Stamford, Connecticut + 65 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Danbury",
          "state": "Connecticut"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00733902"
    }
  ]
}